Quipazine

Last updated

Quipazine
Quipazine.svg
Clinical data
Other names2-(1-Piperazinyl)quinoline; 2-Piperazinoquinoline; 1-(2-Quinolinyl)piperazine; 2-QP
Drug class Non-selective serotonin receptor agonist; Serotonin reuptake inhibitor; Emetic; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • 2-piperazin-1-ylquinoline
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.164.885 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C13H15N3
Molar mass 213.284 g·mol−1
3D model (JSmol)
  • C1CN(CCN1)C2=NC3=CC=CC=C3C=C2
  • InChI=1S/C13H15N3/c1-2-4-12-11(3-1)5-6-13(15-12)16-9-7-14-8-10-16/h1-6,14H,7-10H2 X mark.svgN
  • Key:XRXDAJYKGWNHTQ-UHFFFAOYSA-N X mark.svgN
   (verify)

Quipazine, also known as 1-(2-quinolinyl)piperazine (2-QP), is a serotonergic drug of the aryl piperazine family and an analogue of 1-(2-pyridinyl)piperazine which is used in scientific research. [1] [2] [3] [4] [5] It was first described in the 1960s and was originally intended as an antidepressant but was never developed or marketed for medical use. [1] [6] [4]

Contents

Pharmacology

Pharmacodynamics

Quipazine activities
Target Affinity (Ki, nM)
5-HT1A 230–>10,000
5-HT1B 1,000
5-HT1D 1,000–3,720
5-HT1E ND
5-HT1F ND
5-HT2A 59–2,780
5-HT2B 49–178
5-HT2C 54–339
5-HT3 2.0–4.0 (Ki)
1.0 (EC50 Tooltip half-maximal effective concentration)
5-HT4 >10,000 (guinea pig)
5-HT5A >10,000 (mouse)
5-HT6 3,600
5-HT7 3,033
α1 >10,000 (rat)
α2 5,000 (rat)
β1 5,600
β2 2,900 (rat)
D1 >10,000
D2 >10,000
D2-like 3,920 (rat)
mACh Tooltip Muscarinic acetylcholine receptor>10,000 (rat)
SERT Tooltip Serotonin transporter30
NET Tooltip Norepinephrine transporterND
DAT Tooltip Dopamine transporterND
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [7] [8] [9]

Quipazine is a serotonin 5-HT3 receptor agonist and to a lesser extent a serotonin 5-HT2A receptor agonist, ligand of the serotonin 5-HT2B and 5-HT2C receptors, and serotonin reuptake inhibitor. [1] [2] [7] [8] Activation of the serotonin 5-HT3 is implicated in inducing nausea and vomiting as well as anxiety, which has limited the potential clinical usefulness of quipazine. [1] [2] [3]

Quipazine produces a head-twitch response and other psychedelic-consistent effects in animal studies including in mice, rats, and monkeys. [1] [3] [10] [11] [12] These effects appear to be mediated by activation of the serotonin 5-HT2A receptor, as they are blocked by serotonin 5-HT2A receptor antagonists like ketanserin. [1] [3] [12] The head twitches induced by quipazine are potentiated by the monoamine oxidase inhibitor (MAOI) pargyline. [12] [13] Based on this, it has been suggested that quipazine may act as a serotonin releasing agent and that it may induce the head twitch response by a dual action of serotonin 5-HT2A receptor agonism and induction of serotonin release. [12] [13]

Quipazine did not produce psychedelic effects in humans up to a dose of 25 mg, which was the highest dose tested due to serotonin 5-HT3 receptor-mediated side effects of nausea and gastrointestinal discomfort. [14] [3] Alexander Shulgin has anecdotally claimed that a fully effective psychedelic dose could be reached by blocking serotonin 5-HT3 receptors using the serotonin 5-HT3 receptor antagonist ondansetron. [3] [15]

Quipazine can produce tachycardia, including positive chronotropic and positive inotropic effects, through activation of the serotonin 5-HT3 receptor. [2]

Although quipazine does not generalize to dextroamphetamine in drug discrimination tests of dextroamphetamine-trained rodents, dextroamphetamine and cathinone have been found to partially generalize to quipazine in assays of quipazine-trained rodents. [16] [17] In relation to this, it has been suggested that quipazine might possess some dopaminergic activity, as the discriminative stimulus properties of amphetamine appear to be mediated by dopamine signaling. [16] [17] Relatedly, quipazine has been said to act as a dopamine receptor agonist in addition to serotonin receptor agonist. [12] Conversely however, the generalization may be due to serotonergic activities of amphetamine and cathinone. [18] Fenfluramine has been found to fully generalize to quipazine, but levofenfluramine, in contrast to quipazine, did not generalize to dextroamphetamine. [16] [11]

Chemistry

Quipazine is a substituted piperazine and quinoline. [4] It is structurally related to 6-nitroquipazine, isoquipazine, 1-(2-naphthyl)piperazine (2-NP), and 1-(1-naphthyl)piperazine (1-NP). [4] [3]

Synthesis

It is synthesized by reacting 2-chloroquinoline with piperazine.

Quipazine synthesis: Quipazine synthesis.svg
Quipazine synthesis:

See also

References

  1. 1 2 3 4 5 6 Glennon RA, Dukat M (2 May 2023). "Quipazine: Classical hallucinogen? Novel psychedelic?". Australian Journal of Chemistry. 76 (5): 288–298. doi:10.1071/CH22256. ISSN   0004-9425.
  2. 1 2 3 4 Cappelli A, Butini S, Brizzi A, Gemma S, Valenti S, Giuliani G, et al. (2010). "The interactions of the 5-HT3 receptor with quipazine-like arylpiperazine ligands: the journey track at the end of the first decade of the third millennium". Curr Top Med Chem. 10 (5): 504–526. doi:10.2174/156802610791111560. PMID   20166948.
  3. 1 2 3 4 5 6 7 de la Fuente Revenga M, Shah UH, Nassehi N, Jaster AM, Hemanth P, Sierra S, et al. (March 2021). "Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice". ACS Chem Neurosci. 12 (5): 831–844. doi:10.1021/acschemneuro.0c00291. PMC   7933111 . PMID   33400504.
  4. 1 2 3 4 Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 987. ISBN   978-1-4757-2085-3 . Retrieved 10 December 2024.
  5. ↑ Morton IK, Hall JM (2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Netherlands. p. 244. ISBN   978-94-011-4439-1 . Retrieved 10 December 2024.
  6. ↑ Rodríguez R, Pardo EG (1971). "Quipazine, a new type of antidepressant agent". Psychopharmacologia. 21 (1): 89–100. doi:10.1007/BF00404000. PMID   5567294.
  7. 1 2 "PDSP Database". UNC (in Zulu). Retrieved 4 December 2024.
  8. 1 2 Liu T. "BindingDB BDBM50014407 2-(piperazin-1-yl)quinoline::2-Piperazin-1-yl-quinoline::2-Piperazin-1-yl-quinoline (Quipazine)::2-Piperazin-1-yl-quinoline(Quipazine)::CHEMBL18772::QUIPAZINE". BindingDB. Retrieved 4 December 2024.
  9. ↑ Nelson DL (December 1991). "Structure-activity relationships at 5-HT1A receptors: binding profiles and intrinsic activity". Pharmacol Biochem Behav. 40 (4): 1041–1051. doi:10.1016/0091-3057(91)90124-k. PMID   1816558.
  10. ↑ Glennon RA (1996). "Classical Hallucinogens". Pharmacological Aspects of Drug Dependence. Handbook of Experimental Pharmacology. Vol. 118. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 343–371. doi:10.1007/978-3-642-60963-3_10. ISBN   978-3-642-64631-7.
  11. 1 2 Glennon RA (1988). "Site-Selective Serotonin Agonists as Discriminative Stimuli". Transduction Mechanisms of Drug Stimuli. Vol. 4. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 15–31. doi:10.1007/978-3-642-73223-2_2. ISBN   978-3-642-73225-6. PMID   3293039.{{cite book}}: |journal= ignored (help)
  12. 1 2 3 4 5 Nakagawasai O, Arai Y, Satoh SE, Satoh N, Neda M, Hozumi M, et al. (January 2004). "Monoamine oxidase and head-twitch response in mice. Mechanisms of alpha-methylated substrate derivatives". Neurotoxicology. 25 (1–2): 223–232. Bibcode:2004NeuTx..25..223N. doi:10.1016/S0161-813X(03)00101-3. PMID   14697897.
  13. 1 2 Malick JB, Doren E, Barnett A (March 1977). "Quipazine-induced head-twitch in mice". Pharmacol Biochem Behav. 6 (3): 325–329. doi:10.1016/0091-3057(77)90032-6. PMID   140381.
  14. ↑ Winter JC (1994). "The stimulus effects of serotonergic hallucinogens in animals". NIDA Research Monograph. 146: 157–182. PMID   8742798.
  15. ↑ Halberstadt AL, Geyer MA (2016). "Effect of Hallucinogens on Unconditioned Behavior". Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 159–199. doi:10.1007/7854_2016_466. ISBN   978-3-662-55878-2. PMC   5787039 . PMID   28224459.
  16. 1 2 3 Young R, Glennon RA (1986). "Discriminative stimulus properties of amphetamine and structurally related phenalkylamines". Med Res Rev. 6 (1): 99–130. doi:10.1002/med.2610060105. PMID   3512936.
  17. 1 2 Glennon RA, Rosecrans JA (1981). "Speculations on the mechanism of action of hallucinogenic indolealkylamines". Neurosci Biobehav Rev. 5 (2): 197–207. doi:10.1016/0149-7634(81)90002-6. PMID   7022271.
  18. ↑ Goudie AJ (September 1985). "Comparative effects of cathinone and amphetamine on fixed-interval operant responding: a rate-dependency analysis". Pharmacol Biochem Behav. 23 (3): 355–365. doi:10.1016/0091-3057(85)90006-1. PMID   4048231.
  19. ↑ DE 2006638,Rodriguez R,issued 1970 Chem. Abstr., 73: 98987g (1970).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.